MISSISSIPPI LEGISLATURE REGULAR SESSION 2020 By: Senator(s) Jordan, Jackson (11th) To: Drug Policy; Judiciary, Division A SENATE BILL NO. 2694 1 AN ACT TO AMEND SECTION 41-29-113, MISSISSIPPI CODE OF 1972, 2 TO ADD FLUALPRAZOLAM, FLUBROMAZEPAM, FLUBROMAZOLAM AND CLONAZOLAM 3 TO SCHEDULE I BECAUSE THESE DRUGS HAVE NO LEGITIMATE MEDICAL USE 4 AND HAVE HIGH POTENCY WITH GREAT POTENTIAL TO CAUSE HARM; TO AMEND 5 SECTION 41-29-115, MISSISSIPPI CODE OF 1972, TO REVISE SCHEDULE II 6 TO CLARIFY THE CHEMICAL NAME OF THIAFENTANIL; TO AMEND SECTION 7 41-29-119, MISSISSIPPI CODE OF 1972, TO ADD TO SCHEDULE IV THE 8 DRUGS BREXANOLONE (ZULRESSO) AND SOLRIAMFETOL (SUNOSI) BECAUSE 9 THESE DRUGS RECENTLY HAVE BEEN APPROVED FOR MEDICAL USE BY THE 10 FEDERAL DRUG ADMINISTRATION; AND FOR RELATED PURPOSES. 11 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI: 12 SECTION 1. Section 41-29-113, Mississippi Code of 1972, is 13 amended as follows: 14 41-29-113. 15 SCHEDULE I 16 (a) Schedule I consists of the drugs and other substances, 17 by whatever official name, common or usual name, chemical name, or 18 brand name designated, that is listed in this section. 19 (b) Opiates. Unless specifically excepted or unless listed 20 in another schedule, any of the following opiates, including their 21 isomers, esters, ethers, salts and salts of isomers, esters and S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ G1/2 20/SS08/R210 PAGE 1 (csq\tb) 22 ethers, whenever the existence of these isomers, esters, ethers 23 and salts is possible within the specific chemical designation: 24 (1) Acetyl-alpha-methylfentanyl; 25 (2) Acetyl Fentanyl 26 N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide; 27 (3) AH-7921 (3,4-dichloro-N-[(1-dimethylamino) 28 cyclohexylmethyl]benzamide); 29 (4) Acetylmethadol; 30 (5) Allylprodine; 31 (6) Alphacetylmethadol, except levo-alphacetylmethadol 32 (levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM); 33 (7) Alphameprodine; 34 (8) Alphamethadol; 35 (9) Alpha-methylfentanyl; 36 (10) Alpha-methylthiofentanyl; 37 (11) Benzethidine; 38 (12) Betacetylmethadol; 39 (13) Beta-hydroxyfentanyl; 40 (14) Beta-hydroxy-3-methylfentanyl; 41 (15) Betameprodine; 42 (16) Betamethadol; 43 (17) Betaprodine; 44 (18) Butyrl fentanyl 45 (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide); 46 (19) Clonitazene; S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 2 (csq\tb) 47 (20) Dextromoramide; 48 (21) Diampromide; 49 (22) Diethylthiambutene; 50 (23) Difenoxin; 51 (24) Dimenoxadol; 52 (25) Dimepheptanol; 53 (26) Dimethylthiambutene; 54 (27) Dioxaphetyl butyrate; 55 (28) Dipipanone; 56 (29) Ethylmethylthiambutene; 57 (30) Etonitazene; 58 (31) Etoxeridine; 59 (32) Fentanyl-related substances, meaning any substance 60 not otherwise listed under another schedule and for which no 61 exemption or approval is in effect under Section 505 of the 62 Federal Food, Drug, and Cosmetic Act [21 USC 355] that is 63 structurally related to fentanyl by one or more of the following 64 modifications: 65 (A) Replacement of the phenyl portion of the 66 phenethyl group by any monocycle, whether or not further 67 substituted in or on the monocycle; 68 (B) Substitution in or on the phenethyl group with 69 alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino or nitro 70 groups; S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 3 (csq\tb) 71 (C) Substitution in or on the piperidine ring with 72 alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, 73 amino or nitro groups; 74 (D) Replacement of the aniline ring with any 75 aromatic monocycle whether or not further substituted in or on the 76 aromatic monocycle; and/or 77 (E) Replacement of the N-propionyl group by 78 another acyl group. 79 Fentanyl-related substances include, but are not limited to, 80 cyclopropyl fentanyl, 81 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide); 82 Furanyl-Fentanyl, 83 (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide); 84 valeryl fentanyl, 85 (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide); 86 para-fluorobutyryl fentanyl, 87 (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide); 88 para-methoxybutyryl fentanyl, 89 (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide); 90 para-chloroisobutyryl fentanyl, 91 (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide); 92 isobutyryl fentanyl, 93 (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide); S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 4 (csq\tb) 94 cyclopentyl fentanyl, 95 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide); 96 and 97 ocfentanil, 98 (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetami 99 de); 100 (33) Furethidine; 101 (34) Hydroxypethidine; 102 (35) Ketobemidone (including the optical and geometric 103 isomers); 104 (36) Levomoramide; 105 (37) Levophenacylmorphan; 106 (38) 3-methylfentanyl; 107 (39) 3-methylthiofentanyl; 108 (40) Morpheridine; 109 (41) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine); 110 (42) 111 N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylprop 112 ionamide, its isomers, esters, ethers, salts and salts of isomers, 113 esters and ethers (other names: beta-hydroxythiofentanyl); 114 (43) Noracymethadol; 115 (44) Norlevorphanol; 116 (45) Normethadone; 117 (46) Norpipanone; 118 (47) Para-fluorofentanyl; S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 5 (csq\tb) 119 (48) PEPAP 120 (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine); 121 (49) Phenadoxone; 122 (50) Phenampromide; 123 (51) Phenomorphan; 124 (52) Phenoperidine; 125 (53) Piritramide; 126 (54) Proheptazine; 127 (55) Properidine; 128 (56) Propiram; 129 (57) Racemoramide; 130 (58) Thiofentanyl; 131 (59) Tilidine; 132 (60) Trimeperidine; 133 (61) U-47700, 134 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide. 135 (c) Opium derivatives. Unless specifically excepted or 136 unless listed in another schedule, any of the following opium 137 derivatives, their salts, isomers and salts of isomers, whenever 138 the existence of these salts, isomers and salts of isomers is 139 possible within the specific chemical designation: 140 (1) Acetorphine; 141 (2) Acetyldihydrocodeine; 142 (3) Benzylmorphine; 143 (4) Codeine methylbromide; S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 6 (csq\tb) 144 (5) Codeine-N-Oxide; 145 (6) Cyprenorphine; 146 (7) Desomorphine; 147 (8) Dihydromorphine; 148 (9) Drotebanol; 149 (10) Etorphine (except hydrochloride salt); 150 (11) Heroin; 151 (12) Hydromorphinol; 152 (13) Methyldesorphine; 153 (14) Methyldihydromorphine; 154 (15) Monoacetylmorphine; 155 (16) Morphine methylbromide; 156 (17) Morphine methylsulfonate; 157 (18) Morphine-N-Oxide; 158 (19) Myrophine; 159 (20) Nicocodeine; 160 (21) Nicomorphine; 161 (22) Normorphine; 162 (23) Pholcodine; 163 (24) Thebacon. 164 (d) Hallucinogenic substances. Unless specifically excepted 165 or unless listed in another schedule, any material, compound, 166 mixture or preparation which contains any quantity of the 167 following substances, their salts, isomers (whether optical, 168 positional, or geometric) and salts of isomers, whenever the S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 7 (csq\tb) 169 existence of these salts, isomers and salts of isomers is possible 170 within the specific chemical designation: 171 (1) Alpha-ethyltryptamine; 172 (2) 4-bromo-2,5-dimethoxy-amphetamine; 173 (3) 4-bromo-2,5-dimethoxyphenethylamine; 174 (4) 2,5-dimethoxyamphetamine; 175 (5) 2,5-dimethoxy-4-ethylamphetamine (DOET); 176 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine 177 (2C-T-7); 178 (7) 4-methoxyamphetamine; 179 (8) 5-methoxy-3,4-methylenedioxy-amphetamine; 180 (9) 4-methyl-2,5-dimethoxy-amphetamine; 181 (10) 3,4-methylenedioxy amphetamine; 182 (11) 3,4-methylenedioxymethamphetamine (MDMA); 183 (12) 3,4-methylenedioxy-N-ethylamphetamine (also known 184 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl 185 MDA, MDE, MDEA); 186 (13) N-hydroxy-3,4-methylenedioxyamphetamine (also 187 known as N-hydroxy MDA, N-OHMDA, and 188 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine); 189 (14) 3,4,5-trimethoxy amphetamine; 190 (15) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT); 191 (16) Alpha-methyltryptamine (also known as AMT); 192 (17) Bufotenine; 193 (18) Diethyltryptamine; S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 8 (csq\tb) 194 (19) Dimethyltryptamine; 195 (20) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT); 196 (21) Ibogaine; 197 (22) Lysergic acid diethylamide (LSD); 198 (23) (A) Marijuana (Cannabidiol contained in a legend 199 drug product approved by the Federal Food and Drug Administration 200 or obtained under Section 41-29-136 is exempt under Schedule I); 201 (B) Hashish; 202 (24) Mescaline; 203 (25) Parahexyl; 204 (26) Peyote; 205 (27) N-ethyl-3-piperidyl benzilate; 206 (28) N-methyl-3-piperidyl benzilate; 207 (29) Psilocybin; 208 (30) Psilocyn; 209 (31) Tetrahydrocannabinols, meaning 210 tetrahydrocannabinols contained in a plant of the genus Cannabis 211 (cannabis plant), as well as the synthetic equivalents of the 212 substances contained in the cannabis plant, or in the resinous 213 extractives of such plant, and/or synthetic substances, 214 derivatives, and their isomers with similar chemical structure and 215 pharmacological activity to those substances contained in the 216 plant such as the following: 217 (A) 1 cis or trans tetrahydrocannabinol; 218 (B) 6 cis or trans tetrahydrocannabinol; S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 9 (csq\tb) 219 (C) 3,4 cis or